← Leaderboards
Nagavarakishore Pillarsetty
Sloan-Kettering Inst Can Research
$8,324,037
Attributed
$15,118,130
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2018–25$10M$7.5M$5M$2.5M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,118,130 · 7
By mechanism
R01$8,805,764 · 5
RF1$4,816,476 · 1
R42$1,495,890 · 1
Top collaborators
- Goutam Chakraborty5 shared
- Vladimir Ponomarev5 shared
- Gabriela Chiosis3 shared
- Mark P. Dunphy3 shared
- Christian Brand2 shared
- John L Humm2 shared
- Snehal Patel2 shared
- Abraham Wu2 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Thomas Reiner$4,804,085
- Milind Rajadhyaksha$15,078,152
- Pankaj Chaturvedi$1,198,588
- Junior Arturo Gonzales-Arevalo$407,334
- Robert V Farese$28,829,369
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoClinical TrialsTumorLesionDoseMouse ModelRadiation TherapyFoundationsImagePreparationClinicLeadCellsUptakeCancer PatientMalignant Neoplasm Of ProstateResearch PersonnelResponsePerformanceProductionDrug KineticsPre-ClinicalImaging AgentMonitor
Grant awards (20)
[18F]-PU-AD epichaperome PET imaging probe$845,131
RF1 · FY2025 · AG
Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer$722,240
R01 · FY2025 · CA
Minimizing salivary gland and renal toxicity arising from PSMA-targeted alpha therapy$679,793
R01 · FY2025 · CA · contact PI
[18F]-PU-AD epichaperome PET imaging probe$381,564
RF1 · FY2025 · AG
Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer$135,585
R01 · FY2025 · CA
Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer$678,271
R01 · FY2024 · CA
Minimizing salivary gland and renal toxicity arising from PSMA-targeted alpha therapy$653,256
R01 · FY2024 · CA · contact PI
Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer$114,678
R01 · FY2024 · CA
Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer$729,450
R01 · FY2023 · CA
Minimizing salivary gland and renal toxicity arising from PSMA-targeted alpha therapy$712,866
R01 · FY2023 · CA · contact PI
Development and validation of an intraoperative imaging agent for the peripheral nervous system$668,188
R01 · FY2023 · EB · contact PI
[18F]-PU-AD epichaperome PET imaging probe$3,589,781
RF1 · FY2022 · AG
Non-Invasive Imaging of Oral Cavity Cancer$748,836
R42 · FY2022 · CA
Minimizing salivary gland and renal toxicity arising from PSMA-targeted alpha therapy$687,250
R01 · FY2022 · CA · contact PI
Development and validation of an intraoperative imaging agent for the peripheral nervous system$521,905
R01 · FY2022 · EB · contact PI
Non-Invasive Imaging of Oral Cavity Cancer$747,054
R42 · FY2021 · CA
Development and validation of an intraoperative imaging agent for the peripheral nervous system$508,361
R01 · FY2021 · EB · contact PI
Radioiodinated Multifunctional PARP1 Imaging Probes for Diagnosis and Therapy$661,877
R01 · FY2020 · CA · contact PI
Imaging drug uptake and distribution in chemoradiation therapy of pancreatic cancer$671,441
R01 · FY2019 · CA
Imaging drug uptake and distribution in chemoradiation therapy of pancreatic cancer$660,603
R01 · FY2018 · CA